Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TMC Looks To Add cSSSI Drug, Antibiotic Capabilities With Targanta Offer

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposed merger would see The Medicines Company take over development of oritavancin, stalled at FDA due to “complete response” letter.
Advertisement

Related Content

With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation
The Medicines Co. Pulls European Application For Oritavancin
The Medicines Co. Pulls European Application For Oritavancin
The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY (Part 2 Of 3)
The Medicines Company CEO Clive Meanwell, An Interview With "The Pink Sheet" DAILY (Part 2 Of 3)
Targanta’s Oritavancin Gets FDA “Complete Response”; Additional Phase III Needed
Targanta’s Oritavancin Gets FDA “Complete Response”; Additional Phase III Needed
The Medicines Company’s Curacyte Acquisition Points To A Post-Angiomax Future
Bayer Pulls Remaining Trasylol Supply

Topics

Advertisement
UsernamePublicRestriction

Register

PS068481

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel